Clinical trial · Interventional
In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule
Targeted Molecular Imaging of [68Ga]- Labelling Anti-IGF-1R Affibody Molecule in IGF-1R Overexpression Cancer Patients （Such as Colon Cancer、NSCLC and Gliomas）and Healthy Volunteers
NCT02916394CI-TRIAL-00043551unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators developed \[68Ga\]-labelling Anti-IGF-1R Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting IGF-1R expression status.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Molecular Imaging | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-NODAGA-ZIGF-1R:4：40 | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- 68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++
- description
- Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
- interventionNames
- Radiation: 68Ga-NODAGA-ZIGF-1R:4：40
- type
- EXPERIMENTAL
- label
- 68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++
- description
- Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
- interventionNames
- Radiation: 68Ga-NODAGA-ZIGF-1R:4：40
- type
- EXPERIMENTAL
- label
- 68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Colon cancer, NSCLC and gliomas patients with pathological and gene detection results and did not receive any treatment 2. More than 18 years old 3. A life expectancy of at least 12 weeks 4. Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT) 5. Written informed consent Exclusion Criteria: 1. Could not get pathological and gene detection results 2. Pregnancy 3. do not want to write informed consent。
References
Publications (0)
Data not yet available
No reference posted for this study.